Amgen's Phosphate Binder Loss May Be Genzyme's Gain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
You may also be interested in...
Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
Amgen/Takeda To Re-start Motesanib Lung Cancer Trial
Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee
Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
Enzyme-replacement sales strong as firm builds on renal franchise.